生存期几乎翻倍!BioNTech(BNTX.US)肺癌候选药PRESERVE-003后期试验告捷,肿瘤学转型再获关键支撑

智通财经
Yesterday
【生存期几乎翻倍!BioNTech(BNTX.US)肺癌候选药PRESERVE-003后期试验告捷,肿瘤学转型再获关键支撑】智通财经APP获悉,BioNTech(BNTX.US)周一表示,一项后期临床试验显示,其候选药物gotistobart在一种特定类型肺癌中,较标准治疗带来具有临床意义的总生存期获益。公司称,该试验为PRESERVE-003 III期临床试验,纳入的是在接受既往免疫治疗和化疗后疾病仍出现进展的鳞状非小细胞肺癌患者;与标准治疗化疗相比,gotistobart使生存期几乎翻倍。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10